Marjorie Zauderer

Section Chief, Hematology & Medical Oncology

New York Medical College

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Marjorie Zauderer is the Section Chief of Hematology & Medical Oncology at New York Medical College, USA. Her research focuses on innovative treatments for cancers, particularly in the context of targeted therapies and immunotherapies. Recent publications highlight her work on combinatory approaches to cancer treatment and the genomic implications for advanced cancers, including mesothelioma and lung cancer.

Articles (6)

Year:

2025

Year:

2024

Year:

2024

Year:

2022

Year:

2021

Year:

2021

Collaborators (1)

Zeynep Gümüş

Assistant Professor

Icahn School of Medicine at Mount Sinai

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Marjorie Zauderer

Research Interests

Explore related searches

Contact this professor

About

Articles (6)

Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study

Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U

The BAP1 nuclear deubiquitinase is involved in the nonhomologous end-joining pathway of double-strand DNA repair through interaction with DNA-PK

Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab

The therapeutic implications of the genomic analysis of malignant pleural mesothelioma

Collaborators (1)

Zeynep Gümüş

Make your next move.